Anti-Human ATM (Clone FHC-116) – Purified No Carrier Protein

ATM synthetic peptide SLEIS[+80]QSYTTTQR

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.

Liquid

Purified antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

FHC-116-38-6 activity is directed against human ATM peptide sequence SLEISQSYTTTQR.

ATM is a phosphoinositide 3-kinase-related kinase¹ that functions in the DNA damage response (DDR) pathway by mediating a large phosphosignaling network in conjunction with ATR kinases². ATM is canonically activated by double-strand DNA breaks¹. Phosphosignaling is then used to modulate protein activity and interactions of ATM substrates and to affect their sub- cellular localization<sup>2 . Several hundred ATM substrates have been identified, many of which are involved in DNA repair, cell cycle checkpoints, and/or apoptosis1. ATM kinase activity is usually specific to serine or threonine residues, and less commonly glutamine. Oxidative stress can also induce ATM activity and is used to modulate mitochondrial homeostasis.

ATM dysregulation leads to radiation sensitivity, increases the risk of cancer, and is associated with neurological and immunological disorders2. Additionally, nonsense or missense mutations in the ATM gene cause ataxia telangiectasia, a rare autosomal recessive disorder that causes cerebellar degeneration, ataxia, immunodeficiency, thymic and gonadal atrophy, radiation sensitivity, and a predisposition to cancer1.

FHC-116-38-6 was generated in rabbit for use in immuno-MRM assays using a synthetic peptide derived from residues 363-375 of human ATM that was phosphorylated at S367, SLEIS[ph]QSYTTTQR2,3,4. https://antibodies.cancer.gov/detail/CPTC-ATM-2#CPTC-ATM-2</sup>

ATM is widely expressed and primarily located in the nucleus but is also found in endocytic vesicles in association with beta-adaptin and can be translocated to peroxisomes in response to reactive oxygen species.

p53/TP53, ABL1, BRCA1, TERF1, MRN complex

1 Lee JH, Paull TT. Nat Rev Mol Cell Biol. 22(12):796-814. 2021.
2 Whiteaker JR, Zhao L, Saul R, et al. Radiat Res. 189(5):505-518. 2018.
3 Whiteaker JR, Lundeen RA, Zhao L, et al. Front Immunol. 12:765898. 2021.
4 https://assays.cancer.gov/CPTAC-3211